DVA Stock Overview
Provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 4/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
DaVita Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$150.30 |
52 Week High | US$151.55 |
52 Week Low | US$71.51 |
Beta | 0.87 |
11 Month Change | 8.95% |
3 Month Change | 6.65% |
1 Year Change | 47.99% |
33 Year Change | 13.31% |
5 Year Change | 174.77% |
Change since IPO | 3,588.33% |
Recent News & Updates
Recent updates
DaVita (NYSE:DVA) Has A Pretty Healthy Balance Sheet
Jul 02Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?
Jun 19Are DaVita Inc. (NYSE:DVA) Investors Paying Above The Intrinsic Value?
Jun 04Returns On Capital At DaVita (NYSE:DVA) Have Hit The Brakes
May 22DaVita Stock Is A Hold As It Expands In Latin America
Mar 18Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost
Mar 13Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?
Mar 04DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 16Is DaVita (NYSE:DVA) Using Too Much Debt?
Feb 08DaVita: Assessing After The Rally
Dec 29DaVita Inc.'s (NYSE:DVA) Subdued P/E Might Signal An Opportunity
Dec 24DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet
Nov 08DaVita: Simple And Compelling After Sell-Off
Oct 26Returns On Capital Signal Difficult Times Ahead For DaVita (NYSE:DVA)
Oct 25DaVita: Continued Economic Hurdles, Market Expectations May Be Correct
Oct 05Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?
Aug 14DaVita (NYSE:DVA) Takes On Some Risk With Its Use Of Debt
Jul 31DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold
Jul 21Returns At DaVita (NYSE:DVA) Appear To Be Weighed Down
Jul 18DaVita Inc. (NYSE:DVA) Shares Could Be 41% Below Their Intrinsic Value Estimate
Jul 03What Is DaVita Inc.'s (NYSE:DVA) Share Price Doing?
May 01These 4 Measures Indicate That DaVita (NYSE:DVA) Is Using Debt Extensively
Apr 17Investors Met With Slowing Returns on Capital At DaVita (NYSE:DVA)
Apr 03Are Investors Undervaluing DaVita Inc. (NYSE:DVA) By 40%?
Mar 08DaVita HealthCare Partners Q4 2022 Earnings Preview
Feb 21Moon Capital - DaVita: A Recession-Resistant Cash Generating Machine
Feb 08Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?
Jan 24Is DaVita (NYSE:DVA) A Risky Investment?
Jan 09DaVita: Shares Still Appear Cheap After Outlook Cut, Technicals Suggest Caution
Dec 12DaVita Q3 2022 Earnings Preview
Oct 27Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?
Oct 18DaVita: Solid Valuation And Cash Flow, Price Recovering After SCOTUS Ruling
Sep 28DaVita could benefit from legislation that would return dialysis protection to Medicare
Aug 16We Think DaVita (NYSE:DVA) Is Taking Some Risk With Its Debt
Aug 14DaVita stock dips as peer Fresenius outlook weighed down by labor cost, inflation
Jul 28DaVita: Valuation Turning Attractive
Jul 16Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?
Jul 13Shareholder Returns
DVA | US Healthcare | US Market | |
---|---|---|---|
7D | 7.1% | 2.7% | 3.9% |
1Y | 48.0% | 11.6% | 25.3% |
Return vs Industry: DVA exceeded the US Healthcare industry which returned 11.5% over the past year.
Return vs Market: DVA exceeded the US Market which returned 25.3% over the past year.
Price Volatility
DVA volatility | |
---|---|
DVA Average Weekly Movement | 3.9% |
Healthcare Industry Average Movement | 7.2% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: DVA has not had significant price volatility in the past 3 months.
Volatility Over Time: DVA's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 70,000 | Javier Rodriguez | www.davita.com |
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
DaVita Inc. Fundamentals Summary
DVA fundamental statistics | |
---|---|
Market cap | US$12.61b |
Earnings (TTM) | US$859.62m |
Revenue (TTM) | US$12.52b |
14.7x
P/E Ratio1.0x
P/S RatioIs DVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DVA income statement (TTM) | |
---|---|
Revenue | US$12.52b |
Cost of Revenue | US$8.42b |
Gross Profit | US$4.11b |
Other Expenses | US$3.25b |
Earnings | US$859.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 10.25 |
Gross Margin | 32.79% |
Net Profit Margin | 6.86% |
Debt/Equity Ratio | 360.7% |
How did DVA perform over the long term?
See historical performance and comparison